NGM Bio to Present Safety and Pharmacokinetics Data from Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Ameri...
November 05 2020 - 8:00AM
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company
focused on discovering and developing transformative therapeutics
for patients, today announced that data from its Phase 1 study of
NGM621, a potent anti-complement C3 antibody, will be featured in a
poster presentation at the American Academy of Ophthalmology (AAO)
2020 Virtual. The presentation will include detailed first-in-human
safety, tolerability and pharmacokinetics (PK) findings from single
and multiple intravitreal injections of NGM621 in patients with
geographic atrophy (GA).
Details of the poster presentation are as follows:
Abstract
Title: Inhibition of Complement
Component 3 in GA With NGM621: Phase 1 Dose-Escalation Study
ResultsPresenter Author: Charles C. Wykoff, M.D.,
Ph.D., Director of Research at Retina Consultants Houston and the
Greater Houston Retina Research FoundationDate and
Time: Nov. 13, 2020 at 10:00 AM
ET
All presentations will be available on the NGM Bio website at
https://www.ngmbio.com/rd/presentations-and-publications/.
About NGM621 and Complement C3 Inhibition
NGM621 is a humanized IgG1 monoclonal antibody engineered to
potently inhibit complement C3, with the potential for extended
every eight-week dosing without pegylation. In preclinical models,
NGM621’s high affinity binding to C3 has demonstrated the potential
for potent C3 inhibition. In addition, in well validated animal
models of laser-induced choroidal neovascularization (CNV), C3
inhibition has demonstrated the ability to reduce retinal vascular
leakage, suggesting the potential for NGM621 to prevent CNV
development.
C3 is a key component of the complement system, which helps
orchestrate the body’s response to infection and maintains tissue
homeostasis. The complement cascade can be activated through its
three distinct pathways – classical, lectin and alternative – all
of which converge to activate C3. When this cascade is
dysregulated, the immune response may lead to the development and
progression of GA. Inhibition of C3 represents a promising
therapeutic approach that broadly inhibits downstream effector
functions triggered by the excessive activation of C3, including
inflammation, activation of the adaptive immune system,
opsonization (the marking of a pathogen to be destroyed by
phagocytes, a type of immune cell), phagocytosis and cell lysis
(cell death).
About NGM Biopharmaceuticals, Inc.
NGM is a biopharmaceutical company focused on discovering and
developing novel therapeutics based on scientific understanding of
key biological pathways underlying liver and metabolic diseases,
retinal diseases and cancer. We leverage our biology-centric drug
discovery approach to uncover novel mechanisms of action and
generate proprietary insights that enable us to move rapidly into
proof-of-concept studies and deliver potential first-in-class
medicines to patients. At NGM, we aspire to operate one of the most
productive research and development engines in the
biopharmaceutical industry, with multiple programs in clinical
development. Visit us at www.ngmbio.com for more information.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as “suggesting,” “aspire,” “potential,”
“engineered to” and similar expressions (as well as other words or
expressions referencing future events, conditions or circumstances)
are intended to identify forward-looking statements. These
statements include those related to: the therapeutic potential and
potential extended dosing of NGM621; NGM’s ability to advance
potentially transformative medicines for patients and other
statements that are not historical fact. Because such statements
deal with future events and are based on NGM’s current
expectations, they are subject to various risks and uncertainties,
and actual results, performance or achievements of NGM could differ
materially from those described in or implied by the statements in
this press release. These forward-looking statements are subject to
risks and uncertainties, including, without limitation, the risk
that NGM’s ongoing or future clinical studies in humans may show
that NGM621 is not a tolerable and effective treatment for
geographic atrophy or that extended dosing with NGM621 is not
possible and other risks and uncertainties affecting NGM and its
development programs, as well as those discussed in the sections
titled “Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” in NGM’s quarterly
report on Form 10-Q for the quarter ended June 30, 2020 and future
filings and reports that NGM makes from time to time with the
United States Securities and Exchange Commission. Except as
required by law, NGM assumes no obligation to update these
forward-looking statements or to update the reasons if actual
results differ materially from those anticipated in the
forward-looking statements.
Investor Contact: |
Media
Contact: |
Alex Schwartz |
Liz Melone |
ir@ngmbio.com |
media@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Jul 2024 to Aug 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Aug 2023 to Aug 2024